Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer

Karlstaedt, Anja; Moslehi, Javid; Boer, Rudolf A. de

doi:10.1038/s41569-022-00698-6

Cited by 41 publications

(26 citation statements)

References 200 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, specific oncometabolites, such D-2-hydroxyglutarate and succinate, can affect the heart tissue directly. Metabolic risk factors can cause cardiovascular disease as well as exacerbate tumor proliferation and cancer progression ( 12 ). Currently, the manifestations of cardiac toxicity caused by PD-1/PD-L1 immune checkpoint inhibitors include myocarditis, arrhythmia, conduction disease, myocardial infarction, pericardial disease, Takotsubo syndrome, non-inflammatory left ventricular dysfunction, etc.…”

Section: Discussionmentioning

confidence: 99%

Cardiac infarction caused by PD-1 inhibitor during small cell neuroendocrine carcinoma of the ureter treatment: A case report

Li¹,

Wen²,

Li³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Although small cell neuroendocrine carcinoma of the ureter (ureteral SCNEC) is rare, it always leads to a poor prognosis. Also, no treatment recommendation has been given for ureteral SCNEC, with only PD-1/PD-L1 inhibitors being used for its treatment. Here, we report a case of atypical symptoms of cardiac infarction caused by a PD-1 inhibitor used in the treatment of ureteral SCNEC and hope to address concerns regarding the possible cardiac toxicity caused by PD-1/PD-L1 inhibitors in ureteral SCNEC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Cardiac infarction caused by PD-1 inhibitor during small cell neuroendocrine carcinoma of the ureter treatment: A case report

Li¹,

Wen²,

Li³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…However, it is still unclear whether the long-term risk of CV mortality outweighs the cancer mortality risk for patients with cancer at all sites in a particular window of time. More importantly, as multimorbidity, that is, the simultaneous presence of multiple chronic conditions, including cancer and CVD due to shared risk factors, is becoming an increasing global health problem, and the integrated management of shared risk factors has become a global need to reduce the overall burden of multimorbidity (18)(19)(20)(21). However, current treatment and management protocols that treat cancer as a separate disease entity are likely to ignore the long-term risk of CV death in cancer survivors.…”

Section: Introductionmentioning

confidence: 99%

Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors

Wang

Fan

Yang

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundPrevious studies focused more on the short-term risk of cardiovascular (CV) death due to traumatic psychological stress after a cancer diagnosis and the acute cardiotoxicity of anticancer treatments than on the long-term risk of CV death.MethodsTime trends in the proportions of CV death (PCV), cancer death (PCA), and other causes in deaths from all causes were used to show preliminary relationships among the three causes of death in 4,806,064 patients with cancer from the Surveillance, Epidemiology, and End Results (SEER) program. Competing mortality risk curves were used to investigate when the cumulative CV mortality rate (CMRCV) began to outweigh the cumulative cancer mortality rate (CMRCA) for patients with cancer who survived for more than 10 years. Multivariable competing risk models were further used to investigate the potential factors associated with CV death.ResultsFor patients with cancer at all sites, the PCV increased from 22.8% in the 5th year after diagnosis to 31.0% in the 10th year and 35.7% in the 20th year, while the PCA decreased from 57.7% in the 5th year after diagnosis to 41.2 and 29.9% in the 10th year and 20th year, respectively. The PCV outweighed the PCA (34.6% vs. 34.1%) since the 15th year for patients with cancer at all sites, as early as the 9th year for patients with colorectal cancer (37.5% vs. 33.2%) and as late as the 22nd year for patients with breast cancer (33.5% vs. 30.6%). The CMRCV outweighed the CMRCA since the 25th year from diagnosis. Multivariate competing risk models showed that an increased risk of CV death was independently associated with older age at diagnosis [hazard ratio and 95% confidence intervals [HR (95%CI)] of 43.39 (21.33, 88.28) for ≥ 80 vs. ≤ 30 years] and local metastasis [1.07 (1.04, 1.10)] and a decreased risk among women [0.82 (0.76, 0.88)], surgery [0.90 (0.87, 0.94)], and chemotherapy [0.85 (0.81, 0.90)] among patients with cancer who survived for more than 10 years. Further analyses of patients with cancer who survived for more than 20 years and sensitivity analyses by cancer at all sites showed similar results.ConclusionCV death gradually outweighs cancer death as survival time increases for most patients with cancer. Both the cardio-oncologist and cardio-oncology care should be involved to reduce CV deaths in long-term cancer survivors.

show abstract

“…Cardiovascular diseases are strongly associated with metabolic derangement conditions ( Karlstaedt et al, 2022 ). Nrg4 has been identified as a potential cardioprotective protein, that is, altered in multiple CVDs ( Geissler et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Neuregulin 4 as a novel adipokine in energy metabolism

Liu

Chen

2023

Front. Physiol.

View full text Add to dashboard Cite

Adipose tissue has been shown to play a key role in energy metabolism and it has been shown to regulate metabolic homeostasis through the secretion of adipokines. Neuregulin 4 (Nrg4), a novel adipokine secreted mainly by brown adipose tissue (BAT), has recently been characterized as having an important effect on the regulation of energy homeostasis and glucolipid metabolism. Nrg4 can modulate BAT-related thermogenesis by increasing sympathetic innervation of adipose tissue and therefore has potential metabolic benefits. Nrg4 improves metabolic dysregulation in various metabolic diseases such as insulin resistance, obesity, non-alcoholic fatty liver disease, and diabetes through several mechanisms such as anti-inflammation, autophagy regulation, pro-angiogenesis, and lipid metabolism normalization. However, inconsistent findings are found regarding the effects of Nrg4 on metabolic diseases in clinical settings, and this heterogeneity needs to be further clarified by future studies. The potential metabolic protective effect of Nrg4 suggests that it may be a promising endocrine therapeutic target.

show abstract

Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer

Cited by 41 publications

References 200 publications

Cardiac infarction caused by PD-1 inhibitor during small cell neuroendocrine carcinoma of the ureter treatment: A case report

Cardiac infarction caused by PD-1 inhibitor during small cell neuroendocrine carcinoma of the ureter treatment: A case report

Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors

Neuregulin 4 as a novel adipokine in energy metabolism

Contact Info

Product

Resources

About